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High fat diet-induced changes of 
mouse hepatic transcription and 
enhancer activity can be reversed 
by subsequent weight loss
Majken Siersbæk1, Lyuba Varticovski2, Shutong Yang3, Songjoon Baek2, Ronni Nielsen1, 
Susanne Mandrup1, Gordon L. Hager2, Jay H. Chung3 & Lars Grøntved1
Epigenetic factors have been suggested to play an important role in metabolic memory by trapping and 
maintaining initial metabolic changes within the transcriptional regulatory machinery. In this study we 
fed mice a high fat diet (HFD) for seven weeks followed by additional five weeks of chow, to identify 
HFD-mediated changes to the hepatic transcriptional program that may persist after weight loss. Mice 
fed a HFD displayed increased fasting insulin levels, hepatosteatosis and major changes in hepatic 
gene transcription associated with modulation of H3K27Ac at enhancers, but no significant changes 
in chromatin accessibility, indicating that HFD-regulated gene transcription is primarily controlled by 
modulating the activity of pre-established enhancers. After return to the same body weight as chow 
fed control mice, the fasting insulin, glucose, and hepatic triglyceride levels were fully restored to 
normal levels. Moreover, HFD-regulated H3K27Ac and mRNA levels returned to similar levels as control 
mice. These data demonstrates that the transcription regulatory landscape in the liver induced by HFD 
is highly dynamic and can be reversed by weight loss. This provides hope for efficient treatment of 
early obesity-associated changes to hepatic complications by simple weight loss intervention without 
persistent reprograming of the liver transcriptome.
Diet-induced obesity (DIO) is associated with metabolic changes that significantly increase the risk of cardio-
vascular complications, cancer and diabetes. Recent reports suggest that by 2025 a fifth of the world’s population 
will be obese1. Significant resources are invested in treatment strategies of complications associated with obesity. 
Since obesity arises as a complex interaction between inherited traits and the environment, life style intervention 
strategies, such as exercise and change of diet, are not necessarily obvious. Moreover, despite successful control 
of metabolic dysfunction, such as type 2 diabetes, the remaining metabolic memory leads to increased risk of 
metabolic diseases2–4. Recent studies have suggested that epigenetic factors may contribute to the metabolic mem-
ory in liver tissue5,6, indicating that efforts to identify and modify these factors could be beneficial for metabolic 
intervention and help prevent relapse after treatment.
Epigenetic factors, such as DNA methylation and histone modifications, are associated with transcription 
factor (TF) accessibility to chromatin, enhancer activity and ultimately regulation of gene expression7–10. Specific 
chromatin remodeling and accessibility in these enhancers are manifested in probabilistic transcriptional changes 
of connected genes. A number of techniques, including DNase-, ATAC- and FAIRE-seq, are available to probe 
changes in chromatin accessibility11. Importantly, chromatin accessibility to DNase correlates with TF occupancy, 
emphasizing that this method efficiently identifies regulatory regions genome-wide8,10,12. However, information 
from genome-wide chromatin accessibility by itself does not provide sufficient information of the activity states in 
identified regulatory regions. Thus, parallel detection of enhancer activity can be obtained by ChIP-seq targeting 
H3K27Ac and/or MED1, or by quantification of enhancer RNA expression by GRO-seq12–15.
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Consumption of HFD for several weeks leads to DIO and is associated with hepatosteatosis in laboratory 
animal models, such as C57BL/6 mice. This process is controlled by a range of molecular mechanisms, including 
change of the hepatic transcriptional program5,16,17. Hepatosteatosis is reversible18, yet it has been suggested that 
DIO in rodents followed by weight loss leaves persistent changes in hepatic chromatin organization (probed by 
FAIRE-seq) and persistent pattern of gene expression6. In agreement with these studies, it has been reported 
that hepatic DNA methylation in humans is changed by obesity, and weight loss by bariatric surgery does not 
fully reverse obesity-associated DNA methylation19. In contrast, other studies have reported complete reversal 
of HFD-induced changes of metabolism, hepatic circadian gene transcription and circadian behavior20,21. Here 
we have used an integrated genomics approach to carefully assess whether transcription and enhancer activity 
regulated by HFD are reversible. This included profiling of the transcriptome by RNA-seq, chromatin accessibility 
by DNase-seq and enhancer activity by H3K27Ac ChIP-seq. We show that HFD-induced hepatosteatosis is fully 
reversible at the macroscopic level as well as at the genomic level.
Results
HFD-induced hyperinsulinemia and increased hepatic lipid accumulation are reversed by weight 
loss. To investigate the effects of HFD followed by weight loss, the following experimental setup was used: two 
groups of 12 week old male C57BL/6 J mice were either fed a HFD or a chow diet ad libitum for seven weeks and 
subsequently half of the mice from each group where sacrificed and livers were isolated (Fig. 1a, termed HFD and 
Chow, respectively). The remaining half of the HFD and Chow mice were switched to or continued on a chow diet, 
respectively, for additional five weeks after which livers were isolated. Mice receiving chow for the entire period 
of the experiment are termed Chow-chow and mice initially fed HFD for seven weeks and then shifted to chow 
for five weeks are termed HFD-chow (Fig. 1a). HFD mice displayed significant weight gain (Fig. 1b), hyperinsu-
linemia (Fig. 1c) and triglyceride (TG) accumulation in the liver as compared to chow fed control mice (Fig. 1e,f). 
Following weight loss of the HFD-chow group (Fig. 1b), serum insulin levels returned to normal (Fig. 1c) and no 
difference in serum glucose levels compared to Chow-chow mice was observed (Fig. 1d). Moreover, liver mor-
phology and the accumulated TG levels observed in the HFD group returned to similar levels in HFD-chow as 
in Chow-chow (Fig. 1e,f).
Figure 1. HFD-induced hyperinsulinemia and increased hepatic lipid accumulation is reversed by return 
to chow diet. (a) Male 12 week old C57BL/6 J mice were fed a HFD (broken line, red) or chow diet (solid line, 
black) for seven weeks (7w) where half of the mice were sacrificed (Chow and HFD). The remaining HFD and 
chow mice were switched to or continued on a chow diet for additional five weeks (12w), respectively (Chow-
chow, solid gray line and HFD-chow, broken orange line). (b) Mouse body weight was examined throughout the 
experiment (n > 4). (c) Serum glucose levels (HFD-chow and Chow-chow n = 6) and (d) insulin levels (chow 
and HFD n = 3, Chow-chow and HFD-chow n = 6) after 5 h of fasting. (e) Representative H&E staining of 
liver sections (8 μ m, 20x magnification) and f) quantification of liver TG levels per tissue weight (mg) in Chow, 
HFD, Chow-chow and HFD-chow mice (n = 3). Statistical test was performed by two-tailed t-test. Error bars 
represent standard error of the mean (SEM).
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The liver transcriptome regulated by HFD. To investigate the genome-wide changes of RNA levels in 
the liver induced by HFD and to compare those to livers from mice that underwent subsequent weight loss, we 
performed RNA-seq from livers of three mice in each of the four groups: HFD, Chow, HFD-chow, Chow-chow. 
The libraries were sequenced to a depth of at least 7–11 million uniquely aligned tags (Supplementary Table S1) 
and analyzed for differential mRNA levels using DESeq222. DIO resulted in a dramatic change in the liver tran-
scriptome (Fig. 2a). More than 160 genes showed a significant increase and 140 genes had a decrease in mRNA 
levels when compared to chow-fed mice at FDR < 0.05 when corrected for multiple testing (Fig. 2a). GO term 
analysis suggested that regulated mRNAs are involved in metabolic processes such as lipid, fatty acid and choles-
terol metabolism (Supplementary Table S2).
To obtain a more precise readout of ongoing gene transcription, we prepared RNA-seq libraries from total 
RNA depleted for ribosomal RNA and used random hexamer primers for cDNA synthesis. This allowed us to 
quantify exon as well as intron RNA genome-wide. Intronic RNA reads were specifically used to measure nascent 
RNA expression23. For example, the mRNA level of stearoyl-Coenzyme A desaturase 1 (Scd1), a gene directly 
involved in fatty acid metabolism, was differentially regulated by HFD both at the levels of exon and intron RNA 
reads, indicating that Scd1 was regulated by ongoing transcription of the gene in response to HFD (Fig. 2b). To 
identify genome-wide changes of nascent RNA, we used the iRNA pipeline for specific quantification of exonic 
versus intronic RNA reads23. Genome-wide analysis demonstrated differential intronic RNA levels in 15–32% 
of the exome-regulated mRNAs at FDR between 0.01–0.1 when corrected for multiple testing (Fig. 2c,d). This 
demonstrates significant nascent RNA synthesis from a subset of HFD-regulated genes at the time of analysis, 
yet the vast majority of differential mRNA expression measured after several weeks of HFD exposure could not 
be assigned to ongoing gene transcription at the time of measurement. Importantly, differential nascent RNA 
synthesis was measured from a number of genes known to be involved in DIO, such as upregulation of fatty 
Figure 2. The liver transcriptome of HFD mice before and after weight loss. RNA-seq from livers of three 
mice from each group; Chow, HFD was analyzed for (a) differential mRNA levels using DESeq222. FDR 
value < 0.3 is indicated with heatmap. Data points with FDR > 0.3 are colored black. The number of genes 
with log2 fold change (FC) more or less than zero and FDR < 0.05 is indicated in figure. (b) RNA-seq data 
visualization of Scd1 locus in Chow and HFD mice with focus on exon (left) and intron (right) RNA reads. 
Intronic reads are marked red. (c) Quantification of exon versus intron mRNA reads using the iRNA pipeline23 
in Chow and HFD mice, grouped into HFD-induced or -repressed genes. Regulated genes are scored based 
on FDR (exon) < 0.01 and 1.5 fold change (FC). A z-score is calculated for the RNA-seq data to normalize tag 
counts within exons and introns. FDR values from HFD-regulated intron RNA expression are indicated with 
a heatmap. (d) Fraction of genes up- (yellow) and downregulated (blue) by ongoing transcription after HFD at 
different FDR for HFD-regulated intron RNA expression. (e) Normalized (Reads Per Kilobase Million) intron 
read count from HFD-regulated genes: Scd1, Fasn, Fgf21, Mfsd2a (upregulated by HFD, upper panel) and 
Cyp4a14, Angptl4, Irs2, and Nfil2 (downregulated by HFD, lower panel). Error bars represent SEM.
www.nature.com/scientificreports/
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acid synthase (Fasn), fibroblast growth factor 21 (Fgf21), major facilitator superfamily domain containing 2A 
(Mfsd2a) and Scd1, and downregulation of cytochrome P450, family 4, subfamily a, polypeptide 14 (Cyp4a14), 
angiopoietin-like 4 (Angtpl4), insulin receptor substrate 2 (Irs2) and nuclear factor, interleukin 3 regulated (Nfil3) 
(Fig. 2e). Pathway analysis of intron-regulated genes using the curated reactome database24,25 suggested that ongo-
ing HFD-regulated gene expression is controlled by transcriptional networks regulated by sterol-regulatory ele-
ment binding protein- (SREBP), carbohydrate-responsive element-binding protein (ChREBP) and peroxisome 
proliferator activated receptor (PPAR) (Supplementary Table S3).
Chromatin accessibility remains largely unchanged in response to HFD. To determine whether 
HFD-mediated changes of transcription are associated with changes in chromatin accessibility, we performed 
DNase-seq on livers from HFD and Chow mice. Isolated nuclei from liver tissue of two Chow and HFD mice were 
treated with 40 U or 60 U of DNase I. DNA fragments less than 500 bp were purified using ultra centrifugation 
and sequenced. Sequenced libraries from 40 U and 60 U DNase were combined for each biological replicate and a 
total of more than 74,000 DNase accessible regions were identified. Correlative analysis suggested little variability 
of DNase-seq accessibility among biological replicates (Fig. 3a,b). Interestingly, we detected very few significant 
changes in chromatin accessibility following HFD (Fig. 3c), suggesting that the transcriptional changes in DIO 
are regulated predominantly by changes in pre-established regulatory regions and not by de novo remodeling of 
chromatin.
Changes of H3K27Ac levels in pre-established enhancers following HFD. Enhancer activ-
ity correlates positively with the level of H3K27 acetylation13,26. Therefore, to map modifications in enhancer 
activity in liver tissue in response to HFD we profiled H3K27Ac by ChIP-seq using three biological replicates 
from each group of mice. H3K27Ac enrichment was quantified at all identified DNase accessible regions and 
DESeq2 was used to determine differential acetylation levels. We identified a total of 1,669 DNase accessible 
regions that changed H3K27Ac level in response to HFD at a p-value < 0.01. Corrected for multiple testing and 
FDR < 0.1 reduced this number to 883. The majority of these regions showed an increase in histone acetylation 
(Fig. 4a,b). In agreement with genome-wide DNase accessibility analysis (Fig. 3c), little change in DNase acces-
sibility (Fig. 4c, lower panel) was observed in the differential H3K27-acetylated regions (Fig. 4c, upper panel). 
Figure 3. Chromatin remodeling remains largely unchanged in response to HFD. Scatter plots illustrating 
level of DNase accessibility for replicate 1 and 2 of (a) Chow and (b) HFD and (c) in HFD versus Chow group. 
Differential DNase accessibility is indicated by FDR values identified by DESeq2 (n = 2). FDR levels are shown 
with indicated heatmap, where red represents the most statistical significant data points. Gray data points 
represents differential DNase accessibility at FDR > 0.3.
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To correlate HFD-mediated changes of H3K27Ac with gene expression, we analyzed enrichment of differentially 
regulated H3K27Ac within 100 kb of HFD-regulated genes (intron- and exon-regulated) relative to sets of 200 
randomly selected genes. We observed that HFD-induced genes, both at the intron and exon level, are enriched 
for increased H3K27Ac in nearby regions. In contrast, HFD-repressed gene expression correlated with nearby 
reduced H3K27Ac (Fig. 4d), which is specifically evident for genes regulated at the level of ongoing transcrip-
tion (Fig. 4d, intron reads). For example, the HFD-induced gene Scd1 (Fig. 2b) is flanked by four HFD-induced 
enhancers positioned > 10 kb from the transcriptional start site (TSS) (Fig. 4e). Likewise, the HFD-repressed gene, 
Figure 4. Pre-established enhancers change H3K27Ac level in response to HFD. (a) H3K27Ac ChIP-
seq enrichment was quantified at all identified DNase accessible regions and DESeq2 was used to identify 
differential H3K27Ac. FDR is indicated with heatmap, where red represents the most statistical significant data 
points. Gray data points represents differential H3K27Ac at FDR > 0.3. (b) Differentially H3K27Ac (p < 0.01) 
ranked according to p-value. Corresponding DNase accessibility is plotted in the left panel. (c) H3K27Ac ChIP-
seq and DNase-seq tag densities at regions where HFD induce (red) and reduce (green) H3K27Ac.  
(d) Enrichment of induced (left panel) or reduced (right panel) H3K27Ac relative to multiple rounds (n = 4) 
of 200 randomly selected genes within 100 kb of TSS of genes HFD up- (red) or downregulated (green) genes 
scored by intron or exon reads. Statistical test was performed by two-tailed t-test. Error bars represent SEM. 
(e) Screen shots of DNase accessibility and H3K27Ac regions around Scd1 and (f) Cyp4a14 genes. TSS: 
Transcription start site. Arrows indicate differentially regulated H3K27Ac.
www.nature.com/scientificreports/
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Cyp4a14, is flanked by regions of repressed H3K27Ac in HFD mice (Fig. 4f). Furthermore, in agreement with a 
larger proportion of HFD-induced acetylation at H3K27 sites, we observed a higher percentage of HFD-induced 
genes with nearby enrichment of H3K27Ac as compared to repressed genes (Supplementary Figure S4).
To gain insights into candidate TFs that may be involved in regulation of enhancer activity by HFD, we 
extracted all DNase accessible regions that were differentially regulated at H3K27Ac in response to HFD (at 
p < 0.01) and submitted these for enriched motif analysis using DNA motifs for TFs curated by HOMER27. 
Since a large percentage of activated genes harbors nearby regions with increased H3K27Ac, we focused 
on regions that contained increased H3K27Ac. The ten most enriched motifs identified were binding motifs 
for PPAR, CCAAT-enhancer-binding protein (C/EBP), Hepatocyte nuclear factor 4 (HNF4) and SREBP 
(Supplementary Figure S5a). These possible regulators were also in agreement with the reactome pathway analysis 
(Supplementary Table S3). Quantification of the motif strength within the most enriched motifs at regions with 
either induced or reduced H3K27Ac or randomly selected DNase accessible regions showed that C/EBP, SREBP, 
NF-Y, ATF4 and ATF1 motifs were significantly enriched at regions with increased H3K27Ac (Supplementary 
S5b). The C/EBPα , SREBP and NF-Y transcription factors have previously been shown to regulate expression of 
genes involved in lipogenesis28–31. Moreover, ATF4 depletion has been shown to protect mice from diet-induced 
hepatosteatosis32,33.
Weight loss reverses the HFD-regulated hepatic transcriptome. Replacing HFD with chow 
for five weeks (HFD-chow mice) normalized body weight and reversed the hepatosteatosis observed in HFD 
mice (Fig. 1b,f). To measure effects on the transcriptome, we performed RNA-seq analysis on three livers from 
Chow-chow and HFD-chow mice (Supplementary Table S1) with initial focus on HFD-regulated genes (Fig. 5a). 
Principal component analysis of replicate RNA-seq data from HFD-regulated genes indicated small variabil-
ity between individual mice and none of the chow-containing feeding regimens clustered together with HFD 
mice (Fig. 5b), which was supported by pairwise Pearson correlation analysis between replicate RNA-seq data 
(Supplementary Figure S6a). In addition, principle component analysis and pairwise Pearson correlation anal-
ysis indicated that HFD-chow RNA-seq data clustered together with Chow-chow data, suggesting an overall 
normalization of the HFD-regulated hepatic transcriptome following weight normalization. Statistical analy-
sis using DESeq2 only identified eight HFD-regulated mRNA’s at FDR < 0.05 (corrected for multiple testing) 
that were differentially regulated in HFD-chow as compared to control (Chow-chow) livers (Fig. 5c). Only 
four of these mRNA’s were persistently up- or down regulated (Fig. 5d), indicating that only a very small sub-
set of HFD-regulated genes were not reversed to the levels observed in Chow-chow mice following weight 
loss. Validation of expression by RT-qPCR confirmed similar expression profiles for three out of the four genes 
(Fig. 5e), including collagen alpha1 (III) (Col3a1). Col3a1 has been linked to hepatic fibrosis together with genes 
such as alpha-smooth muscle actin (Acta2), transforming growth factor-β 1 (Tgfb1), desmin (Des) and collagen 
alpha1 (I) (Col1a1)34. None of these additional fibrosis-associated genes showed persistent expression after weight 
loss of HFD-chow mice (Supplementary Figure S6b). This indicates that fibrosis is not pronounced in the liver 
after weight loss. Interestingly, when all annotated genes were included in the differential gene expression anal-
ysis of HFD-chow versus Chow-chow mice, we identified a number of significantly (FDR < 0.05, corrected for 
multiple testing) regulated genes (Supplementary Figure S6c). This group represents genes that were specifically 
changed upon weight loss. Accordingly, only a small fraction of these genes overlaps with HFD-regulated genes 
(Supplementary Figure S6d).
HFD-regulated H3K27Ac levels return to normal after weight loss. It has previously been sug-
gested that HFD-induced chromatin remodeling (probed by FAIRE-seq) in the mouse liver genome persists 
after weight loss6. To investigate whether HFD-induced H3K27Ac changes are maintained after weight loss, we 
profiled H3K27Ac in three livers from HFD-chow mice and compared those to Chow-chow mice. Principle 
component analysis and pairwise Pearson correlation analysis (Supplementary Figure S7) indicated that 
H3K27Ac at HFD-regulated enhancers was similar between HFD-chow and Chow-chow livers, suggesting that 
HFD-regulated H3K27Ac returns to normal after weight loss. We identified 1,324 DNAse accessible regions 
showing differentially regulated H3K27Ac at p-value < 0.01 and reduced these to 254 when corrected for multi-
ple testing at FDR < 0.1 (using DESEq2). The vast majority of these H3K27Ac regions in HFD-chow mice did not 
overlap with those in HFD mice (Fig. 6b) with only a minor common H3K27-acetylated fraction that remained 
after weight loss at p < 0.01 (Fig. 6c). Additional analysis showed that the small fraction of putative persistent 
H3K27Ac was not significantly acetylated after weight loss in HFD-chow mice (Fig. 6d), and when corrected for 
multiple testing revealed that the vast majority of differential H3K27Ac at these regions had a relatively high FDR, 
as compared to H3K27Ac regulated by DIO (Fig. 6e). These data indicate that most putative persistent H3K27Ac 
sites likely represent false positives. Thus, we conclude that overall H3K27Ac changes induced by HFD did not 
persist after weight loss, which agrees with the RNA expression data presented in Fig. 5. Interestingly, an enhancer 
near Abhydrolase Domain Containing 2 (Abhd2) was persistently H3K27-acetylated after weight loss (Fig. 6f), 
which agrees with RNA expression data (Fig. 5d). We observed that differentially H3K27Ac-regulated regions 
after weight loss did not overlap with HFD-regulated H3K27Ac (Fig. 6b). In contrast, these regions represent 
enhancers that are regulated as a consequence of weight loss.
Discussion
Liver dysfunction is linked to pathophysiology of obesity, where hepatosteatosis can lead to insulin resistance, 
type II diabetes35, fibrosis and even cirrhosis36,37. Under normal physiological conditions, the liver handles 
synthesis, storage, and redistribution of lipids, amino acids and glucose in a highly coordinated and dynamic 
manner that is regulated by food intake, environmental, circadian, hormonal, and neuronal stimuli38,39. These 
require enormous hepatic transcriptional plasticity through coordinated crosstalk between the environment and 
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the epigenome, orchestrated by chromatin remodeling enzymes and DNA-bound TFs and their co-factors40. 
When mammals are challenged with HFD for several weeks, it requires significant re-programming of hepatic 
gene transcription to handle excess nutrients. These include adaptive regulation of genes involved in glucose and 
lipid metabolism41, TG accumulation in the liver and disruption of liver circadian clock17,20, which agrees with 
HFD-regulated pathways identified in this study (Supplementary Tables S2 and S3). It has been shown that a shift 
from HFD to regular chow reverses the dysregulated circadian clock at a transcriptional20 as well as at a behavioral 
level21, suggesting that the change of diet can reverse HFD-provoked deregulation of hepatic gene transcription 
and ultimately normalize lipid and glucose metabolism42. However, a recent study has suggested that significant 
changes of chromatin organization and gene transcription in the liver may persist after a shift from HFD to 
Figure 5. HFD-regulated transcriptome returns to normal after weight loss. (a) RNA-seq read count for 
each biological replicate in Chow, HFD, Chow-chow and HFD-chow conditions at HFD-regulated genes (at 
FDR < 0.05). Read counts are visualized as z-scores. (b) Principle component analysis of each biological RNA-
seq replicate in Chow, HFD, Chow-chow and HFD-chow conditions. (c) RNA-seq read count at HFD-regulated 
genes also regulated after weight loss (Genes with FDR < 0.05 is visualized). Average read counts (n = 3) are 
visualized as z-scores. (d) Normalized mRNA expression from selected HFD-regulated genes persistently 
expressed after weight loss. RNA-seq tag count at exons is plotted as Fragments Per Kilobase per Million 
mapped reads (FPKM). Statistical test was performed by two-tailed t-test, n = 3. Error bars represent SEM.  
(e) RT-qPCR validation RNA-seq data. Data is normalized to General transcription factor 2b (Gtf2b) 
expression. Statistical test was performed by two-tailed t-test, n = 3–4. Error bars represent SEM.
www.nature.com/scientificreports/
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Figure 6. HFD-regulated H3K27Ac levels returns to normal after weight loss. (a) H3K27Ac ChIP-seq in livers 
from HFD-chow and Chow-chow mice. Significance levels (FDR) are shown with color codes (right panel), where 
red represents most statistical significant values. Gray data points represents differential H3K27Ac at FDR > 0.3. 
(b) Venn diagram of HFD-regulated H3K27Ac regions at FDR < 0.1 (green) overlapping with differentially 
regulated H3K27Ac regions in HFD-chow mice compared to Chow-chow at FDR < 0.1 (blue). Overlapping 
regions represent putative persistent H3K27Ac deposited by HFD. (c) H3K27Ac level in DIO mice (HFD group) 
compared to DIO after weight loss (HFD-chow group). All HFD-regulated enhancers are shown. H3K27Ac level is 
normalized to a Z-score for each individual replicate. Heatmaps representing p-values (calculated by DESeq2) for 
HFD-regulated H3K27Ac is shown to the right. Red color represents most statistical significant changes. Putative 
persistent regions are identified using a cutoff of p-value < 0.01. (d) Tag densities of putative persistent H3K27Ac 
in three replicates from Chow, HFD, Chow-chow and HFD-chow mice. Green boxplots shows H3K27Ac changes 
at putative persistent acetylated enhancers in Chow and HFD fed mice. Red boxplots shows H3K27Ac changes at 
putative persistent acetylated enhancers in Chow-chow and HFD-chow fed mice. (e) FDR of differentially putative 
persistent H3K27Ac regions in Chow compared to HFD (green, DIO, left panel) and Chow-chow compared to 
HFD-chow (red, weight loss, right panel). (f) H3K27Ac in Chow, HFD, Chow-chow, and HFD-chow mice around 
TSS of the Abhd2 gene. Arrows mark regions with changed H3K27Ac after weight loss.
www.nature.com/scientificreports/
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regular chow diet in DIO mice6. However, that study did not achieve a complete normalization of the weight and 
hepatic TG accumulation after diet reversal6. Thus, it is possible that observed persistent remodeled chromatin 
initiated by HFD may be a consequence of incomplete weight normalization and residual TG accumulation in 
the liver.
In the experimental setup used in the study presented here, mice were fed HFD for seven weeks followed by a 
change to normal chow until they lost the weight they had gained (five weeks), reversed serum hyperinsulinemia 
and TG accumulation in the liver. As expected, HFD regimen resulted in DIO and dramatically changed the liver 
transcriptome. By applying the iRNA-seq pipeline to RNA-seq analysis we identified ongoing transcriptional 
changes promoted by HFD. Interestingly, less than a quarter of the HFD-regulated transcriptome was actively 
transcribed when compared to chow-fed control mice, implying considerable regulation at the level of mRNA 
turnover. Importantly, ongoing transcription regulated by HFD specifically correlated with nearby changes in 
H3K27Ac at DNase accessible regions. In contrast, DNase accessibility itself was not substantially modified by 
HFD, suggesting that HFD does not lead to establishment of new enhancers. Rather, the activity of already estab-
lished enhancers is differentially regulated by the diet. Pathway analysis of differentially expressed genes and DNA 
motif analysis of these enhancers suggested that HFD induces SREBP-, ATF-4- and C/EBP-regulated transcrip-
tional networks, in agreement with previous reports43–46. Thus, the experimental HFD setup used in our study 
resulted in hyperinsulinemia and hepatosteatosis associated with specific changes in enhancer activity and gene 
transcription likely regulated by transcription factors such as SREBP, ATF-4 and C/EBP.
After seven weeks of HFD, mice were switched to chow diet (HFD-chow) and weight changes were carefully 
monitored and compared to control mice of the same age. A significant weight loss was observed within a week 
on chow diet. After two weeks, there were no statistically significant differences in weight between HFD-chow 
and Chow-chow groups. We housed both groups of mice for an additional three weeks on chow diet to maintain 
matched weight before final analysis. Notably, a similar weight loss pattern has been observed in some diet rever-
sal studies21 but not others6. In the study by Leung et al., reporting persistent chromatin structural and transcrip-
tional changes in DIO mice after weight loss, no significant weight loss was observed. Instead, HFD mice stopped 
gaining weight when returned to chow diet6. This study used the same C57BL/6 J mouse strain, thus these marked 
differences may be a consequence of the experimental setup including differences in HFD formula used, age of 
mice at the beginning of treatment, and/or housing facility. For example the diet used in the study by Leung et al. 
(diet formula D12266B) has an overall fat and carbohydrate composition of 32% kcal and 51% kcal, respectively, 
whereas the diet used in this study (diet formula D12327) has a 40% kcal carbohydrate and 40% kcal fat compo-
sition. Interestingly, equal amounts of saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) are 
present in D12266B, whereas D12327 primarily contains SFA. It has previously been shown that administration of 
diet rich in SFA to rodents’ leads to less dramatic change of insulin sensitivity and TG accumulation compared to 
a mixed SFA-MUFA diet47. This implies that the degree of insulin resistance and hepatosteatosis may impact the 
effect of diet reversal. Indeed, the degree of NAFLD has an effect on the beneficial hepatic recovery after bariatric 
surgery in humans48.
When we compared our data to those reported by Leung et al.6 we noticed another important difference in the 
study design applied to identify persistent HFD-induced changes of the liver transcriptome after reversed diet. 
Leung et al. used a study design where three groups of mice were followed for 16 weeks in total. One group received 
chow, a second HFD and a third HFD for 8 weeks followed by chow for 8 weeks. They performed liver RNA-seq 
and FAIRE-seq after 16 weeks for all three groups of mice to discover differential gene expression and chroma-
tin accessibility. This study design allowed Leung et al. to score transcriptional differences in the liver between 
the different feeding regiments at the end point of the study. However, this design did not allow Leung et al.  
to identify actual affects of HFD before the mice returned to chow. To correct for this, the study used previously 
published FAIRE-seq data from HFD fed mice (8 weeks of HFD)5, although without additional statistical analy-
sis. Moreover the study did not use any reference point to HFD-induced changes preceding diet reversal for the 
transcriptomic analysis. Thus, without a HFD reference point for statistical analysis, the subsequent analysis may 
as well score changes that originate from mice placed on normal diet after being obese.
In the study presented here we used a reference point of obese mice before diet reversal. This allowed us to 
statistically score differential gene transcription and enhancer activity that originates specifically from HFD, and 
observe if these HFD-induced changes are expressed after diet reversal. We observed that weight loss after HFD 
resulted in almost complete reversal of the HFD-regulated transcriptome and H3K27 acetylation level. Very few 
HFD-regulated genes, including Col3a1 and Abhd2, did not return to control levels after weight loss. Col3a1 
expression in hepatic stellate cells is associated with liver fibrosis49. We investigated the expression of other genes 
linked to hepatic fibrosis and found no evidence of persistent expression of fibrosis-associated genes. These results 
suggest that initial HFD-mediated hepatic fibrosis may be reversed by diet-induced weight loss. In agreement 
with our conclusions, a number of studies have indicated that early onset fibrosis is significantly reduced after 
weight loss in obese subjects50. Abhd2 has been characterized as triacylglycerol (TAG) lipase and ester hydro-
lase51. Disruption of Abhd2 in mice leads to a decrease in alveolar type II cells in the lung and accumulation of 
macrophages in the lungs52. Moreover, Abhd2 has been linked to vascular smooth muscle cells (SMC) migration53 
but so far no apparent function in liver has been reported. Since Abhd2 is a lipase, it may be involved in mobi-
lization of TGs in a steatotic liver in response to diet-induced weight loss. The potential role of Abhd2 in DIO 
warrants further investigation.
The data presented in this work clearly shows that normalization of hepatic TG accumulation induced by HFD 
and subsequent return to normal body weight normalizes DIO-regulated hepatic transcription and enhancer 
activity. Thus, reversed hepatosteatosis by diet-mediated weight loss is accompanied by normalized transcrip-
tional regulation, illustrating a highly dynamic hepatic transcriptome regulated by diet.
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Materials and Methods
Animal work. All experiments were approved by the ACUC (Animal Care and Use Committee) of the 
NHLBI, NIH and all methods were performed according to relevant guidelines and regulations from ACUC. 
C57BL/6J mice (Jackson Laboratory) were fed either a HFD (D12327, Research Diet, 40% calories from fat (of 
which 78% are SFA, 7% MUFAs and 15% polyunsaturated fatty acids), 40% calories from carbohydrate and 20% 
calories from protein or chow diet (NIH-31, Zeigler Brothers Inc., 8% calories from fat) for seven weeks from 12 
weeks of age (groups termed HFD and Chow, respectively). After seven weeks, half of the HFD and Chow mice 
where sacrificed by CO2 narcosis followed by cervical dislocation, livers were dissected and processed for RNA 
purification, nuclei isolation or frozen in liquid nitrogen for subsequent studies. Blood samples were taken as 
indicated and processed for metabolic measurements. The other half of the HFD and Chow mice where switched 
to or continued on a chow diet, respectively, (termed HFD-chow and Chow-chow) for an additional five weeks. 
See Fig. 1a for experimental setup. Body weights were measured once a week.
Blood glucose measurement. Blood sample was obtained by nicking the tail vein with a sterile scalpel 
blade. One droplet of blood was placed on a glucose test strip and read with a glucometer (Ascensia).
Serum insulin measurement. To measure serum, whole blood, directly drawn from the tail vein, was put 
into a tube with no anti-coagulant. Blood clot was allowed to form at room temperature for 30 min. The clotted 
blood was then centrifuged at 4000 rpm for 15 minutes at 4 °c. Serum insulin level was measured using an ELISA 
kit (EMD Millipore).
Hematoxylin and Eosin (H&E) staining and TG measurements. Frozen liver sections were embed-
ded in tissue freezing medium (Leica, 4020108926), cut in 8 μ m sections, and stained with Mayers Hematoxylin 
(Sigma, MHS16) and aqous Eosin Y solution (Sigma, HT110216), dehydrated with ethanol and TissueClear 
(Sakura, #1466). For TG measurements, ~50 mg of tissue were homogenized in 500 ul isopropanol using 
UltraThorax and subsequently sonicated (QSonica) 2 × 5 sec at 25% amplitude. To measure initial free glycerol 
in samples, 2 μ l sample supernatant and glycerol standards were mixed with 100 μ l free glycerol reagent (Sigma, 
F6428) in duplicates, incubated for 5 min at RT followed by OD measured at 540 nm (Initial absorbance (IA)). 
Subsequently, 25 ul of triglyceride reagent containing lipoprotein lipase (Sigma, T2449) was added and incubated 
for 30 min at 37 °C, followed by glycerol measurement at OD 540 nm (Final absorbance (FA)). For calculation of 
TG content, IA was subtracted from FA values, corrected according to manufacturer’s instructions and divided 
by tissue weight (mg).
RNA isolation and Illumina sequencing. Approximately 5 mg of liver tissue were homogenized using 
UltraThorax and RNA was purified using TRIzol-RNA lysis reagent (ThermoFisher) according to manufacturer’s 
instructions. RNA quality was assessed using the Agilend 2100 Bioanalyzer or the Fragment Analyzer (AATI). 
Total RNA (1 μ g) was either depleted for ribosomal RNA using Ribo-Zero Magnetic Kit (Epicentre) followed 
by cDNA synthesis using random primers or prepared for sequencing using polydT-mediated cDNA synthesis, 
both procedures according to manufacturer’s (Illumina) instructions. Subsequent library preparation was per-
formed using TruSeq RNA sample prep kit (Illumina). Library quality was assessed using the 2100 Bioanalyzer 
or Fragment Analyzer followed by library quantification (Illumina library quantification kit). Sequencing was 
carried out on a HiSeq1500 or HiSeq2500 platform (Illumina). RNA-seq data shown in Fig. 2b–e, is from ribo-
some depleted RNA-seq and data shown in Figs 2a and 5 and Supplementary Figure S6 is from polyA-enriched 
RNA-seq.
DNAse digestion of chromatin and Illumina sequencing. Livers were isolated from mice and nuclei 
were immediately purified using previously described protocol54 and resuspended in buffer (15 mM Tris-HCl pH 
8.0, 15 mM NaCl, 60 mM KCl, 1 mM EDTA, 0.5 mM EGTA, 0.5 mM Spermidine and protease inhibitors) in a final 
concentration of 10 million nuclei per ml. DNase digestions were performed by adding 100 μ l 10X digestion buffer 
(60 mM CaCl2 and 750 mM NaCl) containing 40 U or 60 U of DNase I (Sigma). Digestions were incubated for 3 min 
at 37 °C and reactions were terminated by addition of one volume of stop buffer (50 mM Tris-HCl, 100 mM NaCl, 
0.1% SDS, 100 mM EDTA and 50 μ g/ml Proteinase K (Ambion)). Digested chromatin was incubated at 55 °C for 
2 h and stored at 4 °C until further use. DNase I digestion efficiency was evaluated by quantitative PCR55 and sam-
ples with optimal digestion efficiency were incubated with 90 μ g/ml RNase A (Sigma) for 30 min at 37 °C before 
50–500 bp DNA fragments were purified using ultracentrifugation. DNA was subsequently phenol/chloroform puri-
fied and ethanol precipitated. DNase-seq libraries were constructed according to manufacturer´s (Illumina) instruc-
tions as described previously56. Sequencing was carried out on a HiSeq1500 or HiSeq2500 platform (Illumina).
Chromatin immunoprecipitation and Illumina sequencing. Liver tissue (~60 mg) was homogenized in 
PBS containing formaldehyde (1%), incubated for 10 min with rotation at RT, followed by quenching with glycine 
(0.125 M) for 10 min at RT. Homogenized liver tissue was washed two times in cold PBS, resuspended in 1 ml lysis 
buffer (0.1% SDS, 1% Triton X-100, 150 mM NaCl and 20 mM HEPES pH 7.6) and subsequently sonicated using 
a Biorupter (Diagenode). Chromatin was precleared using protein agarose A/G beads (Santa Cruz, sc-2003) for 
30 min, rotating at 4 °C followed by immunoprecipitation using H3K27Ac antibody (Abcam, Ab4729) and protein 
agarose A/G beads ON at 4 °C. Precipitated chromatin was washed extensively, chromatin was eluted (1% SDS, 1 M 
NaHCO3) by 20 min rotation at RT and decrosslinked at 65 °C ON. DNA was purified using phenol/chloroform 
and precipitated with ethanol. DNA concentration was determined using Quant-iT PicoGreen dsDNA assay kit 
(ThermoScientific, P11496). ChIP-seq libraries were constructed according to manufacturer’s (Illumina) instruc-
tions as described previously56. Sequencing was carried out on a HiSeq1500 platform (Illumina).
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Analysis of RNA, ChIP and DNase sequencing. RNA-seq: Data was aligned to the mouse (mm9) refer-
ence genome using TopHat v.2.0.8 software57 or STAR58. Differential mRNA expression was analyzed by DESeq2 
or iRNA using three biological replicates22,23. DNase-seq: Data was aligned to mm9 using STAR58 or Bowtie59. 
Replicate concordant DNase accessible regions were identified using HOMER at a FDR threshold of 0.001 and tag 
density threshold of 3527. Differentially DNase accessible regions were analyzed using DESeq2 from two biologi-
cal replicates. ChIP-seq: Data was aligned to mm9 using STAR. Differential H3K27Ac was analyzed using DESeq2 
from three biological replicates. Enriched DNA motifs at accessible regions were identified using HOMER27 and 
heatmaps of RNA-seq and ChIP-seq data were generated using MeV60.
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